人胶质母细胞瘤残留病的演化动态
该研究对11例胶质母细胞瘤患者采用荧光引导切除获取69份多区域样本(含浸润肿瘤边缘、室下区和匹配血液)行全外显子组测序,用系统基因组学方法解析肿瘤时空演化。结果提示部分患者浸润性亚克隆在肿瘤生长早期即可出现,治疗后可能播种复发肿瘤,是原发瘤与复发灶之间的「缺失环节」。
要点
- 对11例患者69份多区域样本行全外显子组测序,覆盖浸润边缘与室下区。
- 部分患者浸润性亚克隆可在肿瘤生长早期出现。
- 治疗后浸润性亚克隆可能播种复发肿瘤生长。
核心结论
- 结果提示部分患者浸润性亚克隆可在肿瘤生长早期出现,治疗后可能播种复发肿瘤,代表原发瘤与复发灶之间的「缺失环节」。
- 结果与已知临床表型行为一致,作者认为对浸润脑实质内细胞进行更特异的治疗靶向可能改善患者结局。
研究设计与样本
- 对11例患者采用荧光引导切除获取69份多区域样本(含每例的浸润肿瘤边缘和室下区)及匹配血液行全外显子组测序。
- 采用系统基因组学方法解析每例肿瘤的时空演化,并分析2例有配对原发-复发样本及匹配残留病的患者。
主要发现
- 结果提示部分患者浸润性亚克隆可在肿瘤生长早期出现。
- 治疗后浸润性亚克隆可能播种复发肿瘤生长。
- 复发可发生于局部(约80%)或远处(约20%),常由与原发瘤基因组不同的癌症克隆驱动。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma is the most common and aggressive adult brain malignancy against which conventional surgery and chemoradiation provide limited benefit. Even when a good treatment response is obtained, recurrence inevitably occurs either locally (∼80%) or distally (∼20%), driven by cancer clones that are often genomically distinct from those in the primary tumour. Glioblastoma cells display a characteristic infiltrative phenotype, invading the surrounding tissue and often spreading across the whole brain. Cancer cells responsible for relapse can reside in two compartments of residual disease that are left behind after treatment: the infiltrated normal brain parenchyma and the sub-ventricular zone. However, these two sources of residual disease in glioblastoma are understudied because of the difficulty in sampling these regions during surgery. PATIENT AND METHODS: Here, we present the results of whole-exome sequencing of 69 multi-region samples collected using fluorescence-guided resection from 11 patients, including the infiltrating tumour margin and the sub-ventricular zone for each patient, as well as matched blood. We used a phylogenomic approach to dissect the spatio-temporal evolution of each tumour and unveil the relation between residual disease and the main tumour mass. We also analysed two patients with paired primary-recurrence samples with matched residual disease. RESULTS: Our results suggest that infiltrative subclones can arise early during tumour growth in a subset of patients. After treatment, the infiltrative subclones may seed the growth of a recurrent tumour, thus representing the 'missing link' between the primary tumour and recurrent disease. CONCLUSIONS: These results are consistent with recognised clinical phenotypic behaviour and suggest that more specific therapeutic targeting of cells in the infiltrated brain parenchyma may improve patient's outcome.
引用
- Spiteri I, Caravagna G, Cresswell GD, et al. Evolutionary dynamics of residual disease in human glioblastoma. Ann Oncol. 2019. PMID: 30452544. doi:10.1093/annonc/mdy506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。